CS
MLTX icon

Clear Street’s MoonLake Immunotherapeutics MLTX Stock Holding History

Clear Street’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-801
Closed -$9K – 1041
2022
Q1 		$9K Buy
+801
New +$7.97K ﹤0.01% 267

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Clear Street's MLTX Position: Q2 2022 in Review

Clear Street sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2022, closing a stake of 801 shares — an estimated $9K sold.

Clear Street first reported a position in MLTX in Q1 2022 and held it in 1 quarter. The position peaked at $9K in Q1 2022. 23 funds tracked by Wall St. Rank hold MLTX as of Q2 2022.

  • Clear Street reported no remaining MoonLake Immunotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Clear Street sold 801 MoonLake Immunotherapeutics shares in Q2 2022, an estimated $9K.
  • Clear Street first reported a position in MoonLake Immunotherapeutics in Q1 2022 and held it in 1 quarter.
  • Clear Street's MoonLake Immunotherapeutics position peaked at $9K in Q1 2022.
  • 23 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2022.

Based on Clear Street's 13F filing for Q2 2022, filed 2 Aug 2022.